PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930130
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1930130
Bispecific Antibody Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of bispecific antibody Market
The global bispecific antibody market is witnessing robust growth due to its therapeutic potential in oncology, hematology, and other complex diseases. According to Fortune Business Insights, the market was valued at USD 31.17 billion in 2025, projected to grow to USD 34.72 billion in 2026, and reach USD 91.09 billion by 2034, reflecting a CAGR of 12.8%. In 2025, North America dominated the market with a 51.8% share, driven by advanced biotechnology infrastructure, extensive clinical trials, and supportive reimbursement frameworks.
Bispecific antibodies are bioengineered proteins capable of simultaneously targeting multiple antigens. Their unique mechanism allows for more precise targeting of tumor cells or immune modulation compared with conventional monoclonal antibodies. The rising prevalence of cancer, increasing FDA and EMA approvals, and growing investment in clinical trials are significantly fueling the demand for bispecific antibodies. Key industry players, including AbbVie Inc., Pfizer Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals, are actively developing pipeline candidates to meet rising therapeutic demand.
Market Dynamics
Drivers
The increasing cancer burden coupled with advancements in antibody engineering is a primary growth driver. Conventional therapies often have limitations in relapsed or refractory patient populations, creating demand for novel modalities such as bispecific antibodies. Collaborative research initiatives are enhancing therapeutic applications globally. For instance, in March 2025, Harbour BioMed partnered with AstraZeneca to develop next-generation multi-specific antibodies, supported by a USD 105 million equity investment.
Restraints
High manufacturing complexity and production costs remain major restraints. Bispecific antibodies require sophisticated engineering to maintain dual target specificity, structural stability, and batch consistency. Regulatory quality standards and advanced purification techniques further increase production costs, limiting broader adoption. In August 2025, the U.S. FDA declined approval of Regeneron's odronextamab for follicular lymphoma due to manufacturing issues.
Opportunities
The expansion into earlier lines of therapy presents a significant opportunity. Currently approved mainly for relapsed or refractory cancers, bispecific antibodies may be used in larger patient populations when combined with standard regimens. In December 2024, Janssen-Cilag (Johnson & Johnson) showcased frontline data for TECVAYLI (teclistamab) in multiple myeloma, highlighting potential for early-line combination therapy.
Challenges
Cytokine Release Syndrome (CRS) and neurotoxicity are critical safety challenges, particularly with T-cell engagers. These adverse effects require careful clinical management and step-up dosing, increasing treatment complexity and cost. In November 2024, the American Society of Hematology reported multi-institution rates of CRS and ICANS associated with lymphoma-targeted bispecific antibodies.
Market Trends
A major trend is the shift from intravenous (IV) infusions to subcutaneous (SC) formulations, enhancing patient convenience, compliance, and reduced hospital dependency. Companies are developing stable, low-viscosity, high-concentration SC formulations to maintain efficacy and safety. In November 2024, Alphamab Oncology reported clinical trial data for JSKN033, a subcutaneous co-formulation combining an anti-HER2 bispecific ADC and a PD-L1 inhibitor.
Segmentation Analysis
By Mechanism of Action
The market is divided into T-cell engaging, dual blockers/inhibitors, co-factor mimetics, and others. The T-cell engaging segment is expected to dominate due to its potent anti-tumor activity and ability to overcome resistance in heavily pretreated cancers. In February 2023, Atreca, Inc. collaborated with Xencor, Inc. to launch a T-cell engager program using XmAb bispecific Fc technology.
By Application
Applications include oncology, hematology, ophthalmology, and others. Oncology held the largest market share in 2025 and is projected to account for 41.99% in 2026. The hematology segment is growing at a CAGR of 6.43%.
By Route of Administration
The market is segmented into intravenous (IV), subcutaneous (SC), and others. IV administration dominated in 2025, with a 58.90% share in 2026. SC administration is anticipated to grow at 14.05% CAGR, driven by convenience and improved patient compliance.
By Distribution Channel
Hospital pharmacies dominate due to controlled settings for IV biologics, cold chain storage, and sterile compounding. The segment is expected to hold 67.19% share in 2026. Retail pharmacies are growing at a CAGR of 11.94%, expanding patient access.
Regional Outlook
- North America: USD 21.49B (2025), USD 23.99B (2026), U.S. USD 22.86B in 2026
- Europe: USD 4.36B (2026); U.K. USD 0.84B, Germany USD 1.03B, France USD 0.64B
- Asia Pacific: USD 5.01B (2026); Japan USD 1.59B, China USD 2.04B, India USD 0.3B
- Latin America: USD 0.86B (2026)
- Middle East & Africa (GCC): USD 0.23B (2025)
North America leads due to advanced biotechnology infrastructure, clinical trials, early regulatory approvals, and strong reimbursement systems.
Competitive Landscape
Key players include Bristol-Myers Squibb, Pfizer, Merck, Genentech, AbbVie, Hoffmann-La Roche, Regeneron, and Harbour BioMed. Strategic collaborations, acquisitions, and R&D investments are driving growth. For example, in June 2025, BioNTech SE collaborated with Bristol-Myers Squibb to co-develop investigational bispecific antibodies for solid tumors.
Conclusion
The global bispecific antibody market is expected to grow from USD 31.17 billion in 2025 to USD 91.09 billion by 2034, driven by rising cancer prevalence, advanced antibody engineering, pipeline expansion, and regulatory approvals. Despite manufacturing complexity, high costs, and safety concerns, innovations in subcutaneous formulations, early-line therapy expansion, and strategic collaborations are set to enhance adoption and market growth globally.
Segmentation By Mechanism of Action, Application, Route of Administration, Distribution Channel, and Region
By Mechanism of Action * T-Cell Engaging
- Dual Blockers/ Inhibitors
- Co-factor Mimetics
- Others
By Application * Oncology
- Hematology
- Ophthalmology
- Others
By Route of Administration * Intravenous
- Subcutaneous
- Others
By Distribution Channel * Hospital Pharmacies
- Retail Pharmacies
- Others
By Region * North America (By Mechanism of Action, Application, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Mechanism of Action, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Mechanism of Action, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Mechanism of Action, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Mechanism of Action, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Regulatory Scenarios, By Key Countries/Regions
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Epidemiology- Key Diseases, By Key Countries/ Regions
- 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
5. Global Bispecific Antibody Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Mechanism of Action
- 5.1.1. T-Cell Engaging
- 5.1.2. Dual Blockers/ Inhibitors
- 5.1.3. Co- factor Mimetics
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Oncology
- 5.2.2. Hematology
- 5.2.3. Ophthalmology
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Intravenous
- 5.3.2. Subcutaneous
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Retail Pharmacies
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Bispecific Antibody Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Mechanism of Action
- 6.1.1. T-Cell Engaging
- 6.1.2. Dual Blockers/ Inhibitors
- 6.1.3. Co- factor Mimetics
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Oncology
- 6.2.2. Hematology
- 6.2.3. Ophthalmology
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Intravenous
- 6.3.2. Subcutaneous
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Retail Pharmacies
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Bispecific Antibody Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Mechanism of Action
- 7.1.1. T-Cell Engaging
- 7.1.2. Dual Blockers/ Inhibitors
- 7.1.3. Co- factor Mimetics
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Oncology
- 7.2.2. Hematology
- 7.2.3. Ophthalmology
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Intravenous
- 7.3.2. Subcutaneous
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Bispecific Antibody Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Mechanism of Action
- 8.1.1. T-Cell Engaging
- 8.1.2. Dual Blockers/ Inhibitors
- 8.1.3. Co- factor Mimetics
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Oncology
- 8.2.2. Hematology
- 8.2.3. Ophthalmology
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Intravenous
- 8.3.2. Subcutaneous
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Retail Pharmacies
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Southeast Asia
- 8.5.5. Australia
- 8.5.6. Rest of Asia Pacific
9. Latin America Bispecific Antibody Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Mechanism of Action
- 9.1.1. T-Cell Engaging
- 9.1.2. Dual Blockers/ Inhibitors
- 9.1.3. Co- factor Mimetics
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Oncology
- 9.2.2. Hematology
- 9.2.3. Ophthalmology
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Intravenous
- 9.3.2. Subcutaneous
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Retail Pharmacies
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Bispecific Antibody Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Mechanism of Action
- 10.1.1. T-Cell Engaging
- 10.1.2. Dual Blockers/ Inhibitors
- 10.1.3. Co- factor Mimetics
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Oncology
- 10.2.2. Hematology
- 10.2.3. Ophthalmology
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Intravenous
- 10.3.2. Subcutaneous
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Retail Pharmacies
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.2.1. Bristol-Myers Squibb Company
- 11.2.2. Pfizer Inc
- 11.2.3. Merck & Co., Inc.,
- 11.2.4. Candid Therapeutics
- 11.2.5. Dualitas Therapeutics
- 11.2.6. Genentech, Inc.
- 11.2.7. AbbVie Inc.
- 11.2.8. F. Hoffmann-La Roche Ltd
- 11.2.9. Regeneron Pharmaceuticals Inc.
- 11.2.10. Harbour BioMed.
List of Tables
- Table 1: Global Bispecific Antibody Market Revenue (USD billion) Forecast, By Mechanism of Action, 2021-2034
- Table 2: Global Bispecific Antibody Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 3: Global Bispecific Antibody Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2033
- Table 4: Global Bispecific Antibody Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 5: Global Bispecific Antibody Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 6: North America Bispecific Antibody Market Revenue (USD billion) Forecast, By Mechanism of Action, 2021-2034
- Table 7: North America Bispecific Antibody Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 8: North America Bispecific Antibody Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Bispecific Antibody Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 10: North America Bispecific Antibody Market Revenue (USD billion) Forecast, by Country, 2021-2034
- Table 11: Europe Bispecific Antibody Market Revenue (USD billion) Forecast, By Mechanism of Action, 2021-2034
- Table 12: Europe Bispecific Antibody Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 13: Europe Bispecific Antibody Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2033
- Table 14: Europe Bispecific Antibody Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 15: Europe Bispecific Antibody Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Bispecific Antibody Market Revenue (USD billion) Forecast, By Mechanism of Action, 2021-2034
- Table 17: Asia Pacific Bispecific Antibody Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 18: Asia Pacific Bispecific Antibody Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 19: Asia Pacific Bispecific Antibody Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 20: Asia Pacific Bispecific Antibody Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 21: Latin America Bispecific Antibody Market Revenue (USD billion) Forecast, By Mechanism of Action, 2021-2034
- Table 22: Latin America Bispecific Antibody Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 23: Latin America Bispecific Antibody Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2033
- Table 24: Latin America Bispecific Antibody Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 25: Latin America Bispecific Antibody Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Bispecific Antibody Market Revenue (USD billion) Forecast, By Mechanism of Action, 2021-2034
- Table 27: Middle East & Africa Bispecific Antibody Market Revenue (USD billion) Forecast, by Application, 2021-2034
- Table 28: Middle East & Africa Bispecific Antibody Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 29: Middle East & Africa Bispecific Antibody Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 30: Middle East & Africa Bispecific Antibody Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Bispecific Antibody Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Bispecific Antibody Market Value Share (%), By Mechanism of Action, 2025 & 2034
- Figure 3: Global Bispecific Antibody Market Value Share (%), by Application, 2025 & 2034
- Figure 4: Global Bispecific Antibody Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 5: Global Bispecific Antibody Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Bispecific Antibody Market Value Share (%), by Region, 2025 & 2034
- Figure 7: North America Bispecific Antibody Market Value (USD billion), By Mechanism of Action, 2025 & 2034
- Figure 8: North America Bispecific Antibody Market Value Share (%), By Mechanism of Action, 2025
- Figure 9: North America Bispecific Antibody Market Value (USD billion), by Application, 2025 & 2034
- Figure 10: North America Bispecific Antibody Market Value Share (%), by Application, 2025
- Figure 11: North America Bispecific Antibody Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 12: North America Bispecific Antibody Market Value Share (%), by Route of Administration, 2025
- Figure 13: North America Bispecific Antibody Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Bispecific Antibody Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Bispecific Antibody Market Value (USD billion), by Country, 2025 & 2034
- Figure 16: North America Bispecific Antibody Market Value Share (%), by Country, 2025
- Figure 17: Europe Bispecific Antibody Market Value (USD billion), By Mechanism of Action, 2025 & 2034
- Figure 18: Europe Bispecific Antibody Market Value Share (%), By Mechanism of Action, 2025
- Figure 19: Europe Bispecific Antibody Market Value (USD billion), by Application, 2025 & 2034
- Figure 20: Europe Bispecific Antibody Market Value Share (%), by Application, 2025
- Figure 21: Europe Bispecific Antibody Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 22: Europe Bispecific Antibody Market Value Share (%), by Route of Administration, 2025
- Figure 23: Europe Bispecific Antibody Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Bispecific Antibody Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Bispecific Antibody Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Bispecific Antibody Market Value Share (%), by Country/ Sub-region, 2025
- Figure 27: Asia Pacific Bispecific Antibody Market Value (USD billion), By Mechanism of Action, 2025 & 2034
- Figure 28: Asia Pacific Bispecific Antibody Market Value Share (%), By Mechanism of Action, 2025
- Figure 29: Asia Pacific Bispecific Antibody Market Value (USD billion), by Application, 2025 & 2034
- Figure 30: Asia Pacific Bispecific Antibody Market Value Share (%), by Application, 2025
- Figure 31: Asia Pacific Bispecific Antibody Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 32: Asia Pacific Bispecific Antibody Market Value Share (%), by Route of Administration, 2025
- Figure 33: Asia Pacific Bispecific Antibody Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Bispecific Antibody Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Bispecific Antibody Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Bispecific Antibody Market Value Share (%), by Country/ Sub-region, 2025
- Figure 37: Latin America Bispecific Antibody Market Value (USD billion), By Mechanism of Action, 2025 & 2034
- Figure 38: Latin America Bispecific Antibody Market Value Share (%), By Mechanism of Action, 2025
- Figure 39: Latin America Bispecific Antibody Market Value (USD billion), by Application, 2025 & 2034
- Figure 40: Latin America Bispecific Antibody Market Value Share (%), by Application, 2025
- Figure 41: Latin America Bispecific Antibody Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 42: Latin America Bispecific Antibody Market Value Share (%), by Route of Administration, 2025
- Figure 43: Latin America Bispecific Antibody Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Bispecific Antibody Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Bispecific Antibody Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Bispecific Antibody Market Value Share (%), by Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Bispecific Antibody Market Value (USD billion), By Mechanism of Action, 2025 & 2034
- Figure 48: Middle East & Africa Bispecific Antibody Market Value Share (%), By Mechanism of Action, 2025
- Figure 49: Middle East & Africa Bispecific Antibody Market Value (USD billion), by Application, 2025 & 2034
- Figure 50: Middle East & Africa Bispecific Antibody Market Value Share (%), by Application, 2025
- Figure 51: Middle East & Africa Bispecific Antibody Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 52: Middle East & Africa Bispecific Antibody Market Value Share (%), by Route of Administration, 2025
- Figure 53: Middle East & Africa Bispecific Antibody Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Bispecific Antibody Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Bispecific Antibody Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Bispecific Antibody Market Value Share (%), by Country/ Sub-region, 2025
- Figure 57: Global Bispecific Antibody Market Share (%), by Company, 2025
